Shares of Venus Remedies surged 8% on Thursday after the company won a contract from UNICEF for its antibiotic product, Ceftriaxone 1mg, in the tender for supply of Beta Lactam antibiotics.
This recognition follows the company's earlier achievement of receiving GMP (Good Manufacturing Practices) approval from UNICEF, highlighting its commitment to exceptional quality standards, Venus Remedies said in filing to the stock exchanges.
UNICEF's decision to award the tender to Venus Remedies Limited reflects its dedication to excellence in healthcare, the company informed the stock exchanges.
The Ceftriaxone 1gm has met and exceeded stringent quality criteria, showcasing the commitment to producing top-tier pharmaceutical solutions. This award not only emphasises the products' superior quality but also reinforces the company's role as a trusted partner in global health initiatives, Venus Remedies said in a release.
Ceftriaxone is a kind of antibiotic drug used to treat bacterial infections.
Venus Remedies Ltd said that it will continue to uphold the highest standards of quality, ensuring that its products significantly contribute to the well-being of communities worldwide.
The company added that it remained dedicated to its mission of advancing global health through innovation and excellence in the pharmaceutical industry.
In January, Venus Remedies received marketing authorisation for two new drugs in Europe. The authorizations cover Docetaxel in concentrations of 160mg/8mL, 20mg/1mL, and 80mg/4mL in single vial doses.
Additionally, the company received approval from Malta for a 1g concentration of Gemcitabine. Both drugs are used in chemotherapy treatments for various cancers.
Shares of Venus Remedies were trading 5.24% higher at ₹573.75 apiece on the BSE at 11:30 am.
Catch live market updates with CNBC-TV18.com's blog
This recognition follows the company's earlier achievement of receiving GMP (Good Manufacturing Practices) approval from UNICEF, highlighting its commitment to exceptional quality standards, Venus Remedies said in filing to the stock exchanges.
UNICEF's decision to award the tender to Venus Remedies Limited reflects its dedication to excellence in healthcare, the company informed the stock exchanges.
The Ceftriaxone 1gm has met and exceeded stringent quality criteria, showcasing the commitment to producing top-tier pharmaceutical solutions. This award not only emphasises the products' superior quality but also reinforces the company's role as a trusted partner in global health initiatives, Venus Remedies said in a release.
Ceftriaxone is a kind of antibiotic drug used to treat bacterial infections.
Venus Remedies Ltd said that it will continue to uphold the highest standards of quality, ensuring that its products significantly contribute to the well-being of communities worldwide.
The company added that it remained dedicated to its mission of advancing global health through innovation and excellence in the pharmaceutical industry.
In January, Venus Remedies received marketing authorisation for two new drugs in Europe. The authorizations cover Docetaxel in concentrations of 160mg/8mL, 20mg/1mL, and 80mg/4mL in single vial doses.
Additionally, the company received approval from Malta for a 1g concentration of Gemcitabine. Both drugs are used in chemotherapy treatments for various cancers.
Shares of Venus Remedies were trading 5.24% higher at ₹573.75 apiece on the BSE at 11:30 am.
Catch live market updates with CNBC-TV18.com's blog
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
